{"id":"9d94daa05e4f","type":"article","url":"https://hartvaat.nl/2016/08/16/bio-absorbeerbare-intracoronaire-matrix-ter-preventie-van-ventriculaire-remodell/","title":"Bio-absorbeerbare intracoronaire matrix ter preventie van ventriculaire remodellering na MI","title_en":"Bioabsorbable Intracoronary Matrix for Prevention of Ventricular Remodeling After Myocardial Infarction.","category":"preventie","category_label":"Preventie","professions":["cardioloog"],"tags":["aficamten","laminopathie","myocardinfarct"],"journal":"Journal of the American College of Cardiology","doi":"10.1016/j.jacc.2016.05.053","source_url":"https://doi.org/10.1016/j.jacc.2016.05.053","authors":["Sunil V Rao","Uwe Zeymer","Pamela S Douglas","Hussein Al-Khalidi","Jennifer A White","Jingyu Liu","Howard Levy","Victor Guetta","C Michael Gibson","Jean-Francois Tanguay","Paul Vermeersch","Jérôme Roncalli","Jaroslaw D Kasprzak","Timothy D Henry","Norbert Frey","Oscar Kracoff","Jay H Traverse","Derek P Chew","Jose Lopez-Sendon","Reinilde Heyrman","Mitchell W Krucoff"],"significance":5,"published":"2016-08-16","source_date":"2016-08-16","image":"","kennis":[],"congress":"","summary_en":"This study evaluated a bioabsorbable intracoronary matrix designed to prevent LV remodeling after large MI, testing a novel injectable biomaterial approach for structural myocardial support.","created":"2026-07-03T10:26:16Z","updated":"2026-07-03T13:25:37Z","licence":"Citeer vrij, met bronvermelding en een link naar hartvaat.nl (de url van het record). Samenvattingen zijn redactioneel werk van HartVaat; de oorspronkelijke publicaties blijven van hun uitgevers (doi). Geen medisch advies.","body_markdown":"Studie naar een bio-absorbeerbare intracoronaire matrix om linkerkamerremodellering te voorkomen na myocardinfarct. Innovatieve benadering voor mechanische ondersteuning van het geïnfarceerde myocard.","abstract_original":"BACKGROUND: Bioabsorbable cardiac matrix (BCM) is a novel device that attenuates adverse left ventricular (LV) remodeling after large myocardial infarctions in experimental models. OBJECTIVES: This study aimed to analyze whether BCM, compared with saline control, would result in less LV dilation and fewer adverse clinical events between baseline and 6 months. METHODS: In an international, randomized, double-blind, controlled trial, 303 subjects with large areas of infarction despite successful primary percutaneous coronary intervention (PCI) of ST-segment elevation myocardial infarction (STEMI) were randomized 2:1 to BCM or saline injected into the infarct-related artery 2 to 5 days after primary PCI. The primary outcome was mean change from baseline in LV end-diastolic volume index (LVEDVI) at 6 months. Secondary outcomes included change in Kansas City Cardiomyopathy Questionnaire score, 6-minute walk time, and New York Heart Association functional class at 6 months. The primary safety endpoint was a composite of cardiovascular death, recurrent MI, target-vessel revascularization, stent thrombosis, significant arrhythmia requiring therapy, or myocardial rupture through 6 months. RESULTS: In total, 201 subjects were assigned to BCM and 102 to saline control. There was no significant difference in change in LVEDVI from baseline to 6 months between the groups (mean change ± SD: BCM 14.1 ± 28.9 ml/m(2) vs. saline 11.7 ± 26.9 ml/m(2); p = 0.49). There was also no significant difference in the secondary endpoints. The rates of the primary safety outcome were similar between the 2 groups (BCM 11.6% vs. saline 9.1%; p = 0.37). CONCLUSIONS: Intracoronary deployment of BCM 2 to 5 days after successful reperfusion in subjects with large myocardial infarction did not reduce adverse LV remodeling or cardiac clinical events at 6 months. (IK-5001 for the Prevention of Remodeling of the Ventricle and Congestive Heart Failure After Acute Myocardial Infarction [PRESERVATION I]; NCT01226563)."}